// App-Quantinova.ai

: Late Breaking Abstract - Risk of a severe exacerbation following higher reliever use: post-hoc analysis of SYGMA 1 in mild asthma

Researchers

Presenter

  • Paul O'Byrne

Principal Investigators

  • J. Mark Fitzgerald

  • Eric D. Bateman

  • Peter J. Barnes

  • Nanshan Zhong

  • Christina Keen

  • Millie Wang

  • Rosa Lamarca

  • Margareta Puu

  • Helen K. Reddel

Medical Centers

  • Firestone Institute for Respiratory Health, St Joseph’s Healthcare and Department of Medicine, Michael G. DeGroote School of Medicine, McMaster University, Hamilton, ON, Canada,

  • Institute for Heart and Lung Health, University of British Columbia, Vancouver, BC, Canada,

  • Division of Pulmonology, Department of Medicine, University of Cape Town, Cape Town, South Africa,

  • Airway Disease Infection Section, National Heart and Lung Institute (NHLI), Imperial College London, London, United Kingdom.

  • State Key Laboratory of Respiratory Diseases, First Affiliated Hospital, Guangzhou Medical University, Guangzhou, China,

  • AstraZeneca, Gothenburg, Sweden

  • AstraZeneca, Barcelona, Spain.

  • Woolcock Institute of Medical Research, University of Sydney, Sydney, Australia.

Locations

  • Canada

  • South Africa

  • United Kingdom

  • China

  • Sweden

  • Spain

  • Australia

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Asthma

Biomarkers

  • N/A

Drug/Treatment

  • Terbutaline

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

Phase

  • NA

Study Id's

  • NCT02149199

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved